Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Biotechnology Stocks


easymoney321
5 stars

9378 Reads | 13 Comments | 2 People call this a favourite

This a Blog about biotech stocks.


  • AstraZeneca buys lung drug Pearl for $1.2 B


    91 Reads | 0 Comments | June 10, 2013

    http://finance.yahoo.com/news/astrazeneca-buys-lung-drug-firm-061616209.html


  • Valient buys Bausch & Lomb for $8 billion


    186 Reads | 0 Comments | May 28, 2013

    http://finance.yahoo.com/news/valeant-buy-bausch-lomb-8-133918471.html


  • Hedge fund ups investment in Boston Scientific, St. Jude Medical


    251 Reads | 3 Comments | February 2, 2013

    Hedge fund ups investment in Boston Scientific, St. Jude Medical http://www.bizjournals.com/twincities/news/2013/01/31/blackrock-hedge-fund-ups-investment-in.html?ana=yfcpc Hedge fund giant BlackRock Inc. is stepping up its investment in medical-device companies, including St. Jude Medical and Boston Scientific. New York-based BlackRock (NYSE: BLK) reported in a regulatory filing on Wednesday...


  • YM Biosciences sold for half a billion.


    127 Reads | 0 Comments | December 12, 2012

    Gilead Sciences to Buy YM BioSciences for $510 Million http://ca.finance.yahoo.com/q?s=YM.TO%2C+&ql=0 http://www.bloomberg.com/news/2012-12-12/gilead-sciences-to-buy-ym-biosciences-for-510-million.html?cmpid=yhoo Gilead Sciences Inc. (GILD), the world’s biggest maker of AIDS drugs, agreed to buy YM BioSciences Inc. (YMI)for $510 million to obtain the Canadian company’s research...


  • Merck completed its $7 billion acquisition of Millipore


    1797 Reads | 0 Comments | November 10, 2012

      http://www.genengnews.com/gen-news-highlights/new-emd-millipore-reportedly-the-third-largest-investor-in-life-science-tools-r-d/81243672/   Merck KGaA successful completed its $7 billion acquisition of Millipore yesterday and created the new EMD Millipore division. It will be known as Merck Millipore outside the U.S. and Canada. The segment combines Merck’s EMD Chemicals...


  • Canada's Valeant Pharmaceuticals agrees to buy rival Medicis for about $2.6B


    47 Reads | 0 Comments | September 4, 2012

    Canada's Valeant Pharmaceuticals agrees to buy rival Medicis for about $2.6B http://www.canadianbusiness.com/article/97267--pharmaceutical-takeover-montreal-based-valeant-to-buy-arizona-s-medicis NEW YORK, N.Y. - Valeant Pharmaceuticals International Inc. has agreed to buy dermatology products maker Medicis Pharmaceutical Corp. for about $2.6 billion in cash in a deal to strengthen...


  • Biotech M&A at 4-year high as pharma faces expiring patents


    51 Reads | 0 Comments | August 12, 2012

    Biotech M&A at 4-year high as pharma faces expiring patents http://www.reuters.com/article/2012/08/02/us-healthcare-deals-idUSBRE8711H420120802 Global biotech merger volume has reached levels not seen in four years as big pharmaceutical companies pursue deals to get access to new drugs, with bankers saying therapeutic areas such as cancer, inflammation and autoimmune diseases are proving...


  • Drugmakers see $33bn bout of M&A activity


    41 Reads | 0 Comments | May 7, 2012

    Drugmakers see $33bn bout of M&A activity http://www.ft.com/intl/cms/s/0/27a0a042-9537-11e1-ad38-00144feab49a.html#axzz1uD9S5R9j A recent spate of takeovers in healthcare, as drugmakers seek to replace expiring drug patents, has made it the busiest sector in April with acquisitions around the world worth more than $33bn, according to Dealogic. Completed transactions included AstraZeneca...